A series of alkyl- and halo-substituted 8-(1-piperazinyl)imidazo[1,2-a]
pyrazines were prepared using two approaches, the condensation of alpha-halocarbonyl derivatives with an aminopyrazine or the oxidation-
dehydration of a [(beta-hydroxyalkyl)amino]
pyrazine. These imidazo[1,2-a]
pyrazines were evaluated for their binding affinity to the alpha 1, alpha 2, beta 1, and
beta 2 adrenergic receptors as well as their ability to lower
blood glucose in
insulin resistant hyperglycemic ob/ob mice. Modifications on 8-(1-piperazinyl)imidazo[1,2-a]
pyrazine (4) reduced alpha 2 binding, lowered
hypoglycemic potency, and showed variations in binding to the alpha 1, beta 1, and
beta 2 adrenergic receptors. In addition to 4, the 2-methyl, 3-methyl, and 5-methyl 8-(1-piperazinyl)imidazo[1,2-a]
pyrazines (16k, 25m, and 16f, respectively) displayed high affinity for the alpha 2 receptor and were potent
hypoglycemic agents when compared to 2-amino-7,8-dihydro-4-(1-piperazinyl)-6H-thiopyrano[3,2- d]
pyrimidine (MTP-1403, 2). Receptor binding was modified by use of a 4-methylpiperazine moiety which reduced alpha 1 and beta 1 binding while retaining some
hypoglycemic activity. The structure-activity relationship for heterocyclic alkyl and halo substitution on
biological activity is discussed.